1-4 of 4
Lina van der Straten
Close
Sort by
Journal Articles

Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis

P. Martijn Kolijn, Florentin Späth, Mouhamad Khouja, Paul J. Hengeveld, Lina van der Straten, Nikos Darzentas, Magnus Hultdin, James D. McKay, Christiane Pott, Roel C. H. Vermeulen, Anton W. Langerak
Journal: Blood
Blood (2023) 142 (16): 1399–1403.
https://doi.org/10.1182/blood.2023019609
Published: 2023
Includes: Supplemental data
Journal Articles

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Clinical Trials & Observations
Lina van der Straten, Claudia A. M. Stege, Sabina Kersting, Kazem Nasserinejad, Julie Dubois, Johan A. Dobber, Clemens H. M. Mellink, Anne-Marie F. van der Kevie-Kersemaekers, Ludo M. Evers, Fransien de Boer, Harry R. Koene, John Schreurs, Marjolein van der Klift, Gerjo A. Velders, Ellen van der Spek, Hanneke M. van der Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F. M. Posthuma, Hein P. J. Visser, Ilse Houtenbos, Cecile A. M. Idink, Djamila E. Issa, Ellen C. Dompeling, Henk C. T. van Zaanen, J. Hendrik Veelken, Henriette Levenga, Lidwine W. Tick, Wim E. Terpstra, Sanne H. Tonino, Peter E. Westerweel, Anton W. Langerak, Arnon P. Kater, Mark-David Levin
Journal: Blood
Blood (2023) 142 (13): 1131–1142.
https://doi.org/10.1182/blood.2023020195
Published: 2023
Includes: Supplemental data
Journal Articles

Detecting measurable residual disease beyond 10 −4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL

Paul J. Hengeveld, Michèle Y. van der Klift, P. Martijn Kolijn, Frédéric Davi, François G. Kavelaars, Evert de Jonge, Sandra Robrecht, Jorn L. J. C. Assmann, Lina van der Straten, Matthias Ritgen, Peter E. Westerweel, Kirsten Fischer, Valentin Goede, Michael Hallek, Mark-David Levin, Anton W. Langerak
Journal: Blood
Blood (2023) 141 (5): 519–528.
https://doi.org/10.1182/blood.2022017411
Published: 2023
Includes: Supplemental data
Journal Articles

High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia

Paul Hengeveld, Pieter M. Kolijn, Jeroen A.A. Demmers, Wouter Doff, Julie M.N. Dubois, Melissa Rijken, Jorn Assmann, Lina Van Der Straten, Henk-Jan Boiten, Kirsten J. Gussinklo, Peter J.M. Valk, Peter E. Westerweel, Arnon P. Kater, Anton W. Langerak, Mark-David Levin
Journal: Blood
Blood (2022) 140 (Supplement 1): 9851–9852.
https://doi.org/10.1182/blood-2022-158881
Published: 2022